ACRV

Acrivon Therapeutics, Inc.

2.95

-0.06-1.99%

After Hours: 3.140 +0.190 +6.44%19:59 01/07 EST

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE3.310/3.010

TODAY RANGE2.860-3.560

VOL3.06M

MARKET CAP93.09M

52 WEEK RANGE1.050-8.00

AVG VOL (3M)790.68K

% TURNOVER9.69%

TURNOVER--

P/E (TTM)-1.3858

% RANGE22.86%

EPS(TTM)-2.1288

P/E(FORWARD)-1.4568

P/B0.7237

BVPS4.076

DIVIDEND--

P/S--

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP73.95M

SHARES OUTSTANDING31.56M

NEXT EARNINGS03/24-04/01

FREE FLOAT25.07M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

NASDAQ·5h ago
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates
NASDAQ·22h ago
Acrivon To Deliver Clinical Updates On ACR-368 And ACR-2316 Tomorrow; Stock Soars
TipRanks·1d ago
Acrivon Therapeutics to announce clinical update on Phase 2b ACR-368 studies
Reuters·1d ago
Acrivon Therapeutics Announces Clinical Updates for ACR-368 and ACR-2316 in Ongoing Trials
TipRanks·12/17/2025 12:36
Acrivon to provide ACR-368, ACR-2316 clinical data in January
Reuters·12/17/2025 12:30
Acrivon Therapeutics Announces Upcoming Clinical Data Updates for ACR-368 and ACR-2316 Trials
Reuters·12/17/2025 12:30
ACRIVON THERAPEUTICS TO ANNOUNCE CLINICAL UPDATE ON ITS ONGOING PHASE 2B STUDIES AND PLANNED CONFIRMATORY PHASE 3 TRIAL FOR ACR-368, INITIAL CLINICAL DATA ON ACR-2316, AND OTHER AP3 PIPELINE UPDATES
TipRanks·11/25/2025 11:15
Optimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments
Reuters·11/21/2025 19:01
Acrivon Therapeutics Showcases Advances in Precision Proteomics and Next-Generation Medicine in New Corporate Presentation
TipRanks·11/15/2025 16:50
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV)
TipRanks·11/14/2025 13:50
Analysts Conflicted on These Healthcare Names: Acrivon Therapeutics, Inc. (ACRV) and Bristol-Myers Squibb (BMY)
TipRanks·11/14/2025 12:01
Analysts Have Conflicting Sentiments on These Healthcare Companies: TELA Bio (TELA), Candel Therapeutics (CADL) and Acrivon Therapeutics, Inc. (ACRV)
TipRanks·11/14/2025 11:36
Positive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements
TipRanks·11/14/2025 05:10
Analysts’ Top Healthcare Picks: Acrivon Therapeutics, Inc. (ACRV), Sera Prognostics (SERA)
Seeking Alpha·11/13/2025 22:04
Acrivon Therapeutics GAAP EPS of -$0.47 beats by $0.12

Same Industry

Name/Symbol

Change%

Price

Acrivon Therapeutics, Inc.

ACRV

-1.99%

2.95

Regeneron Pharmaceuticals

REGN

+4.60%

812.27

GridAI Tech

GRDX

+7.17%

4.93

BIONTECH

BNTX

+2.03%

100.08

United Therapeutics Corp.

UTHR

+0.19%

503.69

Vertex Pharmaceuticals Inc

VRTX

+3.37%

484.15

Siga Technologie

SIGA

+2.85%

6.85

Moderna

MRNA

+0.65%

35.89

Charles Riv Labs Intl Inc

CRL

+0.31%

216.77

Medpace Holdings

MEDP

+0.69%

613.09

Talphera Inc

TLPH

+5.88%

1.26

ICON PLC

ICLR

+0.71%

202.92

China Biologic

CBPO

119.99

Iqvia Hldgs Inc

IQV

+1.56%

244.29

MOLECULAR PARTNERS AG

MOLN

-2.69%

4.26

Arcturus Therape

ARCT

+3.48%

6.84

Gilead Sciences Inc

GILD

+2.46%

124.35

PRA Health

PRAH

165.21

Incyte Corp

INCY

+3.67%

110.57

Aptevo Therapeutics Inc

APVO

+12.01%

8.91

Biospecifics

BSTC

+0.15%

88.53

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.